Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa trial of lipsomal ciprofloxacin for the prevention of respiratory tract infections in cystic fibrosis patients.

Next Previous
Trial Profile

Phase IIa trial of lipsomal ciprofloxacin for the prevention of respiratory tract infections in cystic fibrosis patients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2008

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions

Most Recent Events

  • 23 Oct 2008 Results reported at the 22nd Annual North American Cystic Fibrosis conference, according to an Aradigm media release.
  • 30 Jul 2008 Interim results reported in an Aradigm Corporation media release.
  • 14 May 2008 Aradigm Corporation expects to report results in the first quarter of 2008.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top